The pre-ISH 2012 satellite meeting 'Evolving concepts of the renin-angiotensin system' (RAS) took place at Cypress Lakes, Hunter Valley, Australia, on 26-28 September 2012. The satellite meeting attracted more than 60 participants and brought together many leading national and international RAS experts. Delegates soaked up the latest opinions, trends and insights and honed new ideas relating to the RAS. Although the RAS was discovered more than 100 years ago, new components of the RAS and new interactions between RAS components continue to be discovered. The following report reviews the key messages that came out of the highly interactive discussions at the meeting. These included exciting new insights into the role of the RAS in cardiovascular health and disease, and the identification of new therapeutic targets.
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Clinical aspects
Michael Stowasser reviewed the clinical rationale for detection and treatment of primary aldosteronism and described the utility of aldosterone measurement by mass spectrometry. Subsequently, Marko Poglitsch described the use of mass spectrometry to measure angiotensin (Ang) peptides and their metabolites in plasma. Jan Danser reviewed the current and possible future clinical role of renin inhibition. Combination of the renin inhibitor aliskiren with either angiotensin-converting enzyme (ACE) inhibitor or angiotensin type 1 (AT1) receptor blocker (ARB) therapy in diabetic patients with renal impairment (ALTITUDE study) failed to produce benefit. However, study of the combination in heart failure patients (ATMOSPHERE study) is ongoing. Suang Suang Koid described the reduction of myocardial ischemia-reperfusion injury in rats treated with aliskiren. These studies were based on the observation that aliskiren increases myocardial bradykinin levels by an off-target mechanism independent of renin inhibition. The cardioprotective effects of aliskiren were prevented by the bradykinin type 2 (B2) receptor antagonist icatibant. These studies suggest that aliskiren may produce cardiovascular benefits beyond blood pressure control.
AT2 and Mas receptors, ACE2 and Ang-(1-7)
A key theme of the meeting extending across several sessions was the role and interaction between the components of the cardioprotective arm of the RAS, comprising the Ang II type 2 (AT2) and Ang-(1-7) (Mas) receptors, ACE2 and Ang-(1-7). Michael Bader described Mas receptor gene knockout mice with a phenotype of increased cardiovascular disease risk, including increased blood pressure, fat mass, and plasma cholesterol and triglyceride levels. Conversely, transgenic rats with increased expression of Ang-(1-7) had an improved metabolic profile with enhanced glucose tolerance, insulin sensitivity, and insulin-stimulated glucose uptake, decreased triglyceride and cholesterol levels, and a significant decrease in abdominal fat mass, despite normal food intake, whereas circulating insulin and muscle glycogen content were not altered. Moreover, treatment of diabetic rats with an oral (hydroxypropyl-ß-cyclodextrin-based) Ang-(1-7) formulation improved insulin action and ameliorated hyperglycemia. Evidence for a cardioprotective role for ACE2 was provided by transgenic spontaneously hypertensive stroke-prone rats (SHRSP) with over-expression of the ACE2 gene in vascular smooth muscle. In comparison with control SHRSP, ACE2-transgenic SHRSP had reduced blood pressure and cardiac hypertrophy and improved endothelial function. These benefits may have been due to either or both enhanced Ang-(1-7) levels and reduced Ang II levels, as a result of ACE2-mediated conversion of Ang II to Ang-(1-7).
From a clinical perspective, Louise Burrell reported increased ACE2 expression in the heart following myocardial infarction and also in carotid atherosclerotic lesions. Plasma ACE2 levels were increased in patients with cardiovascular and liver disease, diabetes and renal dysfunction, and large prospective studies are required to determine whether plasma ACE2 levels provide information about cardiovascular risk additional to that provided by established risk factors and other biomarkers. Of particular interest, human plasma contains a soluble inhibitor of ACE2, thereby raising questions about the role of ACE2 in Ang II metabolism and Ang-(1-7) production in humans.
Therapeutic potential of AT2 receptor agonists
Muscha Steckelings described the therapeutic effects of the AT2 receptor agonist compound 21 (C21) in a variety of disease models, including cardiovascular disease (myocardial infarction, stroke, hypertension, heart failure), metabolic disease (diabetic nephropathy, obesity with metabolic syndrome), autoimmune diseases (multiple sclerosis, rheumatoid arthritis), spinal cord injury and scleroderma. These actions of C21 were attributed to its marked antiinflammatory and tissue regenerative actions.
Emma Jones described the AT2 receptor agonist properties of ß-Ile 5 -Ang II. Both the AT2 receptor antagonist PD123319 and the Mas receptor antagonist A779 partially prevented the reduction of cardiac fibrosis by ß-Ile 5 -Ang II, suggesting that both the AT2 and Mas receptors contribute to its antifibrotic mechanisms. One possible explanation for this result was that ß-Ile 5 -Ang III, a ß-Ile 5 -Ang II metabolite, might be an agonist of the Mas receptor. Masatsugu Horiuchi described improvement in cognitive function of mice administered C21 by intraperitoneal injection, an effect that was not seen in AT2 receptor gene knockout mice. Surprisingly, the B2 receptor antagonist icatibant prevented the C21-induced cognitive enhancement, consistent with cross-talk between the AT2 and B2 receptors. Colin Summers reported that central infusion of both C21 and Ang-(1-7) produces cerebroprotection in the endothelin-1-induced middle cerebral artery occlusion stroke model; the cerebroprotective effect of C21 was attenuated by the Mas receptor antagonist A779, providing evidence for cross-talk between the AT2 and Mas receptors. In support of this interpretation, Daniel Villela used fluorescence resonance energy transfer (FRET) to demonstrate heterodimerization between the AT2 and Mas receptors in HEK-293 cells transfected with the two receptors. Further evidence of a functional interaction between the AT2 and Mas receptors was the observation that both AT2 and Mas receptor antagonists blocked the AT2 receptor agonist-stimulated expression of the chemokine receptor CX3CR1.
Other actions of the AT2 receptor
Daniel Henrion described the role of the AT2 receptor in flow-mediated dilatation. In addition, the studies of Robert Carey indicate that the endogenous ligand of the renal AT2 receptor is Ang III and not Ang II. In in vivo studies, Ang III, but not Ang II or Ang-(1-7), produced natriuresis and this effect was abolished by the AT2 receptor antagonist PD123319. These data raise the question as to why the renal AT2 receptor does not respond to Ang II and whether the putative renal AT2 receptor is different from that characterized in non-renal tissues. In in vitro studies, the AT2 receptor was shown to heterodimerize with dopamine 1 receptors; such heterodimerization may change the specificity of the AT2 receptor and explain why the renal AT2 receptor is specific for Ang III.
Therapeutic potential of AT2 receptor antagonists
In contrast to the therapeutic effects of AT2 receptor agonists described above, Maree Smith and Praveen Anand argued for the use of AT2 receptor antagonists in the treatment of neuropathic pain. AT2 receptors are expressed in sensory neurons and AT2 receptor stimulation induces p38 and p42/p44 mitogen-activated protein kinase (MAPK) activation, neurite outgrowth and excitability in cultured cells of neuronal origin. Moreover, AT2 receptor antagonists produce dose-dependent analgesia in rodent models of neuropathic pain. These compounds are currently in clinical trial for neuropathic pain states. It remains to be seen whether clinical application of AT2 receptor antagonists interferes with the therapeutic effects of AT2 receptor stimulation such as may occur with the increased Ang II levels that accompany ARB therapy.
Insulin-regulated aminopeptidase (IRAP)
In addition to the AT2 receptor, IRAP represents a therapeutic target for cognitive enhancement. Siew Yeen Chai reviewed studies revealing that the receptor for Ang-(3-8) (Ang IV) is IRAP, and IRAP inhibitors are being evaluated as possible memory-enhancing compounds. IRAP inhibition accelerates spatial learning and facilitation of memory consolidation, provides neuroprotection against ischemic injury and reduces vascular remodeling and thrombosis following vascular injury. In addition, IRAP inhibition was neuroprotective in mouse models of Alzheimer's disease. Tracey Gaspari described reduced collagen deposition, cardiac fibrosis and inflammation, without alteration in blood pressure, in aged mice with IRAP gene knockout, suggesting a role for IRAP in the cardiovascular effects of aging.
Mechanisms of Ang II-induced hypertension and cardiovascular pathology
Duncan Campbell reviewed the many different mechanisms implicated in the pressor effect of Ang II administration. These include vasoconstrictor, neural, renal, immune, inflammatory and matrix metalloproteinase-related mechanisms, and some of these mechanisms were discussed by subsequent speakers. Given that most recent studies of Ang II pressor mechanisms were performed with subcutaneous administration of Ang II at doses much higher than are required to increase blood pressure by intravenous administration, the question arises whether subcutaneous and intravenous Ang II administration increase blood pressure by different mechanisms. Evidence for different mechanisms of action of subcutaneous and intravenous Ang II includes the weight loss caused by subcutaneous Ang II administration and the report by Kate Denton that low-dose subcutaneous Ang II administration (50 ng/kg/min) actually reduces blood pressure in female rats.
A key event in the regulation of vascular smooth muscle contraction is the phosphorylation of the myosin light chain. Gervaise Loirand described Ang II/AT1 receptormediated Jak2 activation and phosphorylation of the guanine nucleotide exchange factor Arhgef1, producing RhoA activation in vascular smooth muscle, and their role in atherosclerosis and hypertension. In support of the Jak2/ Arhgef1 pathway as a therapeutic target in hypertension, Jak2 inhibition or genetic deletion of Arhgef1 prevented the vasoconstrictor response to Ang II in vitro and prevented or reversed the hypertensive response to subcutaneous Ang II infusion in vivo. Moreover, a role for Arhgef1 in Ang II-induced vascular inflammation was demonstrated by quantification of leukocyte adhesion using intravital microscopy and by cytokine profiling of wild type versus Arhgef1 gene knockout mice.
Grant Drummond discussed the role of the innate immune system (monocytes, macrophages, neutrophils and other granulocytes) in Ang II-induced hypertension and inflammation. Inflammasome-deficient (NLTP3 -/-) mice had a markedly attenuated blood pressure response to Ang II. Moreover, Jeffrey Moore reported that the chemokine C-C motif receptor 2 (CCR2) antagonist INCB3344 attenuated Ang II-induced hypertension and vascular macrophage accumulation in mice. However, these mechanisms may not be specific for Ang II-mediated hypertension and vascular inflammation given that Chris Chan observed similar effects of CCR2 antagonism in deoxycorticosterone/salt-induced hypertension.
Many studies have implicated T cell activation and vascular infiltration in Ang II-induced hypertension. However, the finding by Anthony Vinh that the AT2 receptor agonist CGP42112 reversed T cell activation and vascular infiltration without affecting the pressor response to Ang II administration suggests that the pressor effect of Ang II may be independent of T cell activation and vascular infiltration.
Additional evidence for Ang II-mediated vascular disease is provided by studies of diabetic retinopathy and retinopathy of prematurity. Jennifer Wilkinson-Berka discussed the role of Ang II in promoting advanced glycation end-product damage to the retina by reducing glyoxylase 1 expression, and in the up-regulation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and reactive oxygen species in the pathogenesis of retinopathy of prematurity.
A role for alpha calcitonin gene-related peptide (CGRP) in providing protection from the effects of Ang II was suggested by studies of CGRP knockout mice. Sarah-Jane Smillie reported that CGRP knockout mice had an exaggerated hypertensive response to Ang II with increased vascular inflammation and remodeling.
The work of Thomas Coffman clearly demonstrated a critical role for renal AT1A receptors in the hypertensive effects of subcutaneous Ang II administration in mice. He has extended these studies by selectively deleting AT1A receptor expression in specific renal compartments. Deletion of the AT1A receptor from proximal tubule (PT) cells reduced basal blood pressure, and although PT AT1A receptor deletion did not modify the acute hypertensive effects of intravenous Ang II, it attenuated the hypertensive effects of chronic subcutaneous Ang II administration, in association with a reduction in PT fluid reabsorption and cumulative sodium balance and altered PT expression of sodium transporters.
Sex differences in the RAS
The implication of T cells in the pressor response to Ang II administration led Kathryn Sandberg to investigate whether the sex of the T cells influenced the pressor response. Male RAG1 -/-mice (deficient in both T cells and B cells) have an attenuated pressor response to subcutaneous Ang II administration. The pressor response to Ang II was restored by adoptive transfer of male, but not female, T cells to RAG1 -/-mice, and the same result was achieved with adoptive transfer of male, but not female, CD4 + and CD8 + T cell subsets. Regulatory T cells (Treg) are proposed to play a protective role in Ang II-induced hypertension, and their infiltration of perivascular adipose tissue may protect vasculature from hypertension-induced endothelial dysfunction following their adoptive transfer to male RAG1 -/-mice infused with Ang II. Consistent with this putative vasculo-protective role of Treg cells, there was greater infiltration of female than male FoxP3 + CD4 + Treg and FoxP3 + CD8 + Treg in perivascular adipose tissue. These studies lead to the conclusion that T cells are important contributors to sex differences in basal blood pressure, hypertension and cardiovascular disease.
Kate Denton provided further evidence for sex-specific differences in the pressor response to Ang II. The hypotensive effect of subcutaneous administration of a low dose of Ang II (50 ng/kg/min) in female, but not male, rats was shown to be mediated by increased AT2 receptor expression in female rats. Moreover, the AT2 receptor plays an important role in the hemodynamic adjustments to pregnancy, and failure to up-regulate AT2 receptor expression may contribute to pre-eclampsia and hypertension in pregnancy. In addition, ACE2 gene knockout increases blood pressure of pregnant mice, suggesting that ACE2 also plays a role in the hemodynamic adjustments to pregnancy, mediated through Ang-(1-7) stimulation of the Mas receptor. These studies indicate that the AT2 and Mas receptors may be therapeutic targets for the prevention and treatment of pre-eclampsia and hypertension in pregnancy.
Signaling mechanisms
Many questions remain concerning the signaling mechanisms by which different members of the angiotensin peptide family alter cell function. Walter Thomas described a functional genomics approach to the identification of mechanisms by which the AT1 receptor trans-activates the epidermal growth factor receptor (EGFR). He established a human mammary cell line transfected with the AT1 receptor that shows a robust activation of the EGFR upon stimulation with Ang II, and he is performing a high-throughput short interfering RNA (siRNA) screening approach to identify genes involved in AT1 receptor-EGFR trans-activation that may provide therapeutic targets for the treatment of both cancer and cardiovascular disease.
